• An FDA advisory committee previously voted unanimously to recommend approval of Moderna’s mRNA-based influenza vaccine, mFlusiva, for adults aged 50 and over, after late-stage trials showed it was around 27% more effective than a standard flu shot.
• If the FDA and other health authorities follow this advice, mFlusiva could become the first mRNA flu vaccine and strengthen Moderna’s position in respiratory vaccines for older adults, who represent most flu-related hospitalizations.
• We’ll now assess how the advisory panel’s unanimous backing for mFlusiva may influence Moderna’s broader investment narrative and pipeline outlook.

AI is about to change healthcare. These 38 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Moderna Investment Narrative Recap

To own Moderna today, you need to believe its mRNA platform can move beyond a shrinking COVID franchise into a broader, recurring respiratory and specialty portfolio. The unanimous FDA panel backing for mFlusiva directly supports that story by potentially adding a sizable non COVID respiratory product, but it does not remove the near term risk that seasonal vaccine demand and pricing keep revenues volatile while Moderna remains loss making.

The most relevant recent announcement here is Moderna’s June 16 update outlining an operating model built around multiple vaccines, with up to three potential launches in 2027 and 2028, including a separate seasonal flu shot. mFlusiva now looks like a concrete step toward that plan, but pipeline execution risk and ongoing cost control efforts still shape how powerful these launches could be as future catalysts.

Yet against the excitement around mFlusiva, investors should also be aware of how sustained pricing pressure on vaccines could...

Moderna’s narrative projects $3.2 billion revenue and $407.1 million earnings by 2029.

Uncover how Moderna's forecasts yield a $46.10 fair value, a 24% downside to its current price.

Exploring Other Perspectives

Before this mFlusiva update, the most bearish analysts were assuming only about 2.5% annual revenue growth and no profits for at least three years, which is far more cautious than the consensus view that Moderna’s broader pipeline and cost cuts could ease COVID reliance, so it is worth comparing how those expectations might shift if new mRNA vaccines start to gain real traction.

Explore 6 other fair value estimates on Moderna - why the stock might be worth 29% less than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Moderna research is our analysis highlighting 1 key reward that could impact your investment decision.
• Our free Moderna research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Moderna's overall financial health at a glance.

Contemplating Other Strategies?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Capitalize on the AI infrastructure supercycle with our selection of the 49 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 14 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.